The Department of Justice announced Dec. 12 that Pfizer Inc. will pay $55 million plus interest to resolve allegations that its Wyeth unit promoted the drug Protonix for unapproved uses (United States v. Wyeth LLC).
Specifically, the settlement resolves allegations that Wyeth illegally introduced and caused the introduction into interstate commerce of a misbranded drug (Protonix) between February 2000 and June 2001. Pfizer acquired Wyeth in 2009.
DOJ explained that Wyeth manufactured and promoted Protonix (pantoprazole sodium), a proton pump inhibitor (PPI) used by physicians to treat various forms of gastroesophageal reflux disease (GERD). The government alleged that ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.